Sequent Scientific Limited , a prominent player in the pharmaceutical sector, has announced its financial results for the second quarter of fiscal year 2026, revealing a mixed performance with revenue growth but a decline in profitability.

Revenue Growth

The company reported a consolidated revenue of ₹4,261.40 million for Q2 FY26, marking a significant increase from ₹3,731.80 million in the same quarter of the previous year. This 14.2% year-over-year growth demonstrates Sequent Scientific's ability to expand its market presence and sales despite challenging market conditions.

Profitability Decline

Despite the revenue growth, Sequent Scientific experienced a decrease in its profit after tax. The company's profit after tax for Q2 FY26 stood at ₹196.00 million, down from ₹251.00 million in the corresponding quarter of the previous year, representing a 21.9% decline.

Financial Highlights

Here's a breakdown of key financial metrics for Q2 FY26:

Operational Performance

The company's cost of materials consumed increased to ₹1,827.90 million in Q2 FY26, up from ₹1,353.40 million in the same quarter last year. This rise in material costs may have contributed to the pressure on profitability despite revenue growth.

Employee benefits expense also saw an increase, reaching ₹816.90 million compared to ₹670.40 million in Q2 FY25, reflecting potential investments in human resources or increased workforce costs.

Corporate Developments

Sequent Scientific's board has approved the unaudited financial results for the quarter and half-year ended September 30, 2025. The company is currently awaiting NCLT approval for its composite scheme of amalgamation involving multiple subsidiaries, which could potentially reshape its corporate structure and operations in the future.

Market Position

With a steady increase in revenue, Sequent Scientific appears to be maintaining its market position in the pharmaceutical industry. However, the decline in profitability suggests that the company may be facing challenges in managing costs or experiencing pricing pressures in its key markets.

Conclusion

Sequent Scientific's Q2 FY26 results present a mixed picture, with strong revenue growth offset by declining profitability. The company's ability to manage costs and improve profit margins while maintaining revenue growth will be crucial for its performance in the coming quarters.

Sequent Scientific , a prominent player in the life sciences sector, has initiated a postal ballot process to seek shareholder approval for the appointment of Mr. Anuj Poddar as a Non-Executive Director. This move comes as part of the company's efforts to strengthen its board with experienced professionals.

Key Details of the Appointment

• Mr. Anuj Poddar was initially appointed as an Additional Non-Executive Director on September 5, 2025.
• The company is now seeking shareholder approval to formalize his position as a Non-Executive Director.
• If approved, Mr. Poddar will serve as a nominee of The Carlyle Group on Sequent Scientific's board.

Voting Process

• The remote e-voting period will run from October 4 to November 2, 2025.
• Results of the postal ballot are expected to be announced by November 4, 2025.
• The cut-off date for voting eligibility is set at September 26, 2025.

About Anuj Poddar

Mr. Anuj Poddar brings a wealth of experience to Sequent Scientific:

• Currently serves as Managing Director and Asia Co-Head of Global Portfolio Solutions at Carlyle, a global investment firm managing $465.00 billion in assets.
• Previously held the position of Managing Director and CEO at Bajaj Electricals, where he drove significant transformation and value creation.
• Has over 13 years of experience with Viacom18 Media, playing a key role in the company's growth.
• Holds a rank in Chartered Accountancy and is an Aspen Fellow.

Board's Rationale

The Nomination and Remuneration Committee and the Board of Directors believe that Mr. Poddar's induction will bring valuable experience to Sequent Scientific, particularly in light of increasing business complexities and evolving regulatory landscapes.

Remuneration

It's noteworthy that Mr. Poddar will not receive any sitting fees or commission for his role. However, he will be entitled to reimbursement of expenses incurred on behalf of the company, in line with company policy.

Sequent Scientific's move to appoint Mr. Anuj Poddar reflects the company's commitment to enhancing its board's expertise and strategic capabilities. Shareholders will have the opportunity to vote on this appointment, potentially shaping the future direction of the company's governance and strategic initiatives.